PPH:NSD-VanEck Vectors Pharmaceutical ETF (USD)

ETF | Health | NASDAQ Global Market

Last Closing

USD 56.28

Change

+1.41 (+2.57)%

Market Cap

USD 0.25B

Volume

0.03M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors? US Listed Pharmaceutical 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Pharmaceutical Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

Inception Date: 20/12/2011

Primary Benchmark: MVIS US Listed Pharmaceutical 25 NR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: 0.41%

Management Expense Ratio: 0.36 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-04-08 )

Largest Industry Peers for Health

Symbol Name Mer Price(Change) Market Cap
IBB iShares Biotechnology ETF 0.47 %

-0.26 (-0.20%)

USD 7.79B
BBH VanEck Biotech ETF 0.35 %

+0.18 (+0.11%)

USD 0.45B
PSCH Invesco S&P SmallCap Health Ca.. 0.29 %

-0.14 (-0.34%)

USD 0.22B
PTH Invesco DWA Healthcare Momentu.. 0.60 %

-0.57 (-1.42%)

USD 0.15B
GNOM Global X Genomics & Biotechnol.. 0.00 %

-0.09 (-0.85%)

USD 0.10B
BTEC Principal Healthcare Innovator.. 0.42 %

-0.30 (-0.86%)

USD 0.04B
CNCR Loncar Cancer Immunotherapy ET.. 0.79 %

-0.25 (-1.73%)

USD 0.02B
FTXH First Trust Nasdaq Pharmaceuti.. 0.60 %

-0.06 (-0.23%)

USD 0.02B

ETFs Containing PPH

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange (NASDAQ Global Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.31% 55% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.31% 55% F 70% C-
Trailing 12 Months  
Capital Gain -5.93% 40% F 72% C
Dividend Return 0.78% 83% B 16% F
Total Return -5.16% 40% F 71% C-
Trailing 5 Years  
Capital Gain -21.42% 20% F 48% F
Dividend Return 7.14% 100% F 29% F
Total Return -14.28% 20% F 46% F
Average Annual (5 Year Horizon)  
Capital Gain -2.21% 10% F 29% F
Dividend Return -0.37% 20% F 30% F
Total Return 1.84% 100% F 50% F
Risk Return Profile  
Volatility (Standard Deviation) 10.61% 80% B- 86% B+
Risk Adjusted Return -3.46% 10% F 28% F
Market Capitalization 0.25B 67% D+ 44% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.